TO EXCLUSIVE LICENSE AGREEMENT Sample Clauses

TO EXCLUSIVE LICENSE AGREEMENT. AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT, dated July 24, 2008 (this “Amendment”), between S.L.A. PARMA AG (the “Licensor”), and VENTRUS BIOSCIENCES, INC., as assignee of Paramount Biosciences, LLC (the “Licensee”).
Sample 1Sample 2
AutoNDA by SimpleDocs
TO EXCLUSIVE LICENSE AGREEMENT. This Amendment No. 1 to the Exclusive License Agreement (AMENDMENT 1) is made and entered into as of December 23, 2014 by and between arGEN-X NV (formerly arGEN-X BV)(LICENSEE) and the Board of Regents (LICENSOR) of The University of Texas System (SYSTEM).
Sample 1Sample 2
TO EXCLUSIVE LICENSE AGREEMENT. This AMENDMENT No. 1 to the Exclusive License Agreement covering UMMC 03-17 (“Amendment”) is made effective as of January 7, 2004 (the “Amendment Date”), between UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (“Medical School”), a public institution of higher education of the Commonwealth of Massachusetts having an address of 50 Xxxx Xxxxxx Xxxxx, Xxxxxxxxx, Xxxxxxxxxxxxx 00000, and CYTRX CORPORATION (“Company”), a Delaware corporation having an address of 10000 Xxx Xxxxxxx Xxxxxxxxx, Suite 650, Los Angeles, California 90049. Capitalized terms used in this Amendment that are not otherwise defined in this Amendment have the same meanings as they are defined in the Agreement (as defined below).
Sample 1Sample 2
TO EXCLUSIVE LICENSE AGREEMENT. THIS AMENDMENT No. 2 TO EXCLUSIVE LICENSE AGREEMENT is entered into on March 6, 2018 (the “Effective Date of the Amendment”), by and between DURECT Corporation (“Company”) and Virginia Commonwealth University Intellectual Property Foundation (“VCUIPF”).
Sample 1
TO EXCLUSIVE LICENSE AGREEMENT. This AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), effective as of January 29, 2019 (“Amendment Effective Date”), is entered into by and between MeiraGTx Limited (registered number 9501998), having a place of business located at 00 Xxxxxxxxx Xxxx, Xxxxxx, Xxxxxx Xxxxxxx, X0 0XX United Kingdom (“MeiraGTx”) and UCL Business PLC (registered number 02776963), whose registered office is The Network Building, 00 Xxxxxxxxx Xxxxx Xxxx, Xxxxxx X0X 0XX Xxxxxx Xxxxxxx (“UCLB”). MeiraGTx and UCLB are each sometimes referred to herein as a “Party” and collectively referred to herein as the “Parties”.
Sample 1
TO EXCLUSIVE LICENSE AGREEMENT. This Fourth Amendment to Exclusive License Agreement (the “Fourth Amendment”) is entered into by and between The Xxxxx Xxxxxxx University, a Maryland corporation having an address at 0000 Xxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, XX 00000 (“JHU”) and Kala Pharmaceuticals, Inc., a Delaware corporation having an address at 000 Xxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx, XX 00000 (“Kala” or “Company”).
Sample 1
TO EXCLUSIVE LICENSE AGREEMENT. This Amendment No. 1 (this “Amendment #1”) to the Exclusive License Agreement, dated as of September 26, 2014 (the “License Agreement”), by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC., a Kansas non-profit §501 (c)(3) corporation, having its principal place of business at 3000 Xxxxxxx Xxxxxxxxx, Xxxxxx Xxxx, Xxxxxx 00000 (“KUCTC” or “Licensor”), and REATA PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business located at 5000 Xxxxxx Xxxxx, Xxxxx, Xxxxx 00000 (“REATA” or “Licensee”), is entered into as of the date of the last signature below (the “Effective Date of Amendment #1”).
Sample 1
AutoNDA by SimpleDocs
TO EXCLUSIVE LICENSE AGREEMENT. This Amendment No. 1 to Exclusive License Agreement (the “Amendment No. 1”), effective as of September 8, 2014 (the “Effective Date”), is made by and between Memorial Xxxxx-Xxxxxxxxx Cancer Center, a New York corporation with principal offices at 0000 Xxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 (“MSKCC”), and Juno Therapeutics, Inc., a Delaware corporation having a principal place of business at 000 Xxxxxxxx Xxxxxx Xxxxx, Xxxxx 000, Xxxxxxx, Xxxxxxxxxx 00000 (“Licensee”).
Sample 1

Related to TO EXCLUSIVE LICENSE AGREEMENT

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).

  • Non-Exclusive License NCPS grants Company a revocable, non-exclusive, non-transferable and non-sublicensable license during the Term to view-only access the PPEX ATS through the PPEX Site and its related software and other applications and technology for the sole purpose of viewing information about Company and Company Securities and Trades of Company Securities. This license is in addition to the license Company has and is required to maintain during the Term (as defined below) with NCPS’s affiliate, North Capital Investment Technology, Inc., for TransactAPI pursuant to a separate Software and Services License Agreement (“SSLA”). The technology covered by the licenses outlined in this Section 2 is collectively referred to herein as the “Technology”.

  • Non-Exclusive License Grant Subject to the terms and conditions of this Agreement, Takeda hereby grants to Licensee a non-exclusive, sublicensable (subject to Section 3.3 (Sublicensing)) right and license under the Takeda Technology and Takeda’s interest in the Joint Technology to: (a) Develop the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Takeda Territory solely for the purpose of Exploiting such Licensed Products in the Field in the Licensee Territory, or as required in order for Licensee to comply with its diligence obligations set forth in Section 5.2 (Development Diligence Obligations) and (b) Manufacture the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Takeda Territory.

  • Exclusive License Grant Subject to the terms and conditions of this Agreement, Licensee hereby grants to Takeda an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Licensee Technology and Licensee’s interest in the Joint Technology to Exploit the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Takeda Territory.

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • PATENT LICENSE AGREEMENT EXCLUSIVE PHS and Licensee agree as follows:

  • Trademark License Agreement Buyer shall have executed and delivered to Sellers the Trademark License Agreement.

  • Software License Agreement McDATA agrees that all Licensed Software will be distributed to Customers subject to a Software License Agreement (including warranty statement), along with a McDATA Manual, in a manner which is (a) no less protective of BROCADE's Intellectual Property Rights in the Licensed Software than the form attached hereto as Exhibit D, and (b) legally enforceable in the jurisdictions in which the Licensed Software, as incorporated into the McDATA Products, is distributed.

  • License Agreements (a) Each Borrower and Guarantor shall (i) promptly and faithfully observe and perform all of the material terms, covenants, conditions and provisions of the material License Agreements to which it is a party to be observed and performed by it, at the times set forth therein, if any, (ii) not do, permit, suffer or refrain from doing anything that could reasonably be expected to result in a default under or breach of any of the terms of any material License Agreement, (iii) not cancel, surrender, modify, amend, waive or release any material License Agreement in any material respect or any term, provision or right of the licensee thereunder in any material respect, or consent to or permit to occur any of the foregoing; except, that, subject to Section 9.19(b) below, such Borrower or Guarantor may cancel, surrender or release any material License Agreement in the ordinary course of the business of such Borrower or Guarantor; provided, that, such Borrower or Guarantor (as the case may be) shall give Agent not less than thirty (30) days prior written notice of its intention to so cancel, surrender and release any such material License Agreement, (iv) give Agent prompt written notice of any material License Agreement entered into by such Borrower or Guarantor after the date hereof, together with a true, correct and complete copy thereof and such other information with respect thereto as Agent may request, (v) give Agent prompt written notice of any material breach of any obligation, or any default, by any party under any material License Agreement, and deliver to Agent (promptly upon the receipt thereof by such Borrower or Guarantor in the case of a notice to such Borrower or Guarantor and concurrently with the sending thereof in the case of a notice from such Borrower or Guarantor) a copy of each notice of default and every other notice and other communication received or delivered by such Borrower or Guarantor in connection with any material License Agreement which relates to the right of such Borrower or Guarantor to continue to use the property subject to such License Agreement, and (vi) furnish to Agent, promptly upon the request of Agent, such information and evidence as Agent may reasonably require from time to time concerning the observance, performance and compliance by such Borrower or Guarantor or the other party or parties thereto with the material terms, covenants or provisions of any material License Agreement.

  • Grant of Exclusive License 1. Licensor hereby grants to Licensee an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.

Time is Money Join Law Insider Premium to draft better contracts faster.